Cardiac Adverse Events After Chimeric Antigen Receptor (CAR) T Cell Therapies: an Updated Systematic Review and Meta-analysis

Overview

Journal Cardiooncology

Publisher Biomed Central

Specialty Oncology

Date 2024 Aug 20

PMID 39164789

Authors

Saba Maleki

Zahra Esmaeili

Niloofar Seighali

Arman Shafiee

Sara Montazeri Namin

Mohammad Amin Tofighi Zavareh

Sima Shamshiri Khamene

Izat MohammadKhawajah

Michael Nanna

Azin Alizadeh-Asl

Jennifer M Kwan

Kaveh Hosseini

Affiliations

Soon will be listed here.

Abstract

Purpose: Chimeric antigen receptor (CAR) T-cell therapy is a new revolutionary method for treating refractory or relapsed hematologic malignancies, CAR T-cell therapy has been associated with cytokine release syndrome (CRS) and cardiotoxicity. We directed a systematic review and meta-analysis to determine the incidence and predictors of cardiovascular events (CVE) with CAR T-cell therapy.

Methods: We investigated PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for studies reporting cardiovascular outcomes in CAR-T cell recipients. The study protocol was listed in the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42023478602). Twenty-three studies were included in this study.

Results: The pooled incidence of CVE was 54% for arrhythmias, 30% for heart failure, 20% for cardiomyopathy, 10% for acute coronary syndrome, and 7% for cardiac arrest. Patients with CVE had a higher incidence of cytokine release syndrome grade ≥ 2 (RR 2.36, 95% CI 1.86-2.99). The incidence of cardiac mortality in our meta-analysis was 2% (95% CI: 1%-3%). Left ventricular ejection fraction decline was greater in the CVE group (-9.4% versus -1.5%, p < 0.001). Cardiac biomarkers like BNP, CRP, creatinine, and ferritin were also elevated.

Conclusions: CAR T-cell therapy commonly leads to cardiotoxicity, mediated by cytokine release syndrome. Vigilant monitoring and tailored treatments are crucial to mitigate these effects. Importantly, there's no significant difference in cardiac mortality between groups, suggesting insights for optimizing preventive interventions and reducing risks after CAR T-cell therapy.

References

Fitzgerald J, Weiss S, Maude S, Barrett D, Lacey S, Melenhorst J . Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2016; 45(2):e124-e131. PMC: 5452983. DOI: 10.1097/CCM.0000000000002053. View

Lefebvre B, Kang Y, Smith A, Frey N, Carver J, Scherrer-Crosbie M . Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study. JACC CardioOncol. 2020; 2(2):193-203. PMC: 7413146. DOI: 10.1016/j.jaccao.2020.04.012. View

Burstein D, Maude S, Grupp S, Griffis H, Rossano J, Lin K . Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience. Biol Blood Marrow Transplant. 2018; 24(8):1590-1595. DOI: 10.1016/j.bbmt.2018.05.014. View

Goldman A, Maor E, Bomze D, Liu J, Herrmann J, Fein J . Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J Am Coll Cardiol. 2021; 78(18):1800-1813. PMC: 8562317. DOI: 10.1016/j.jacc.2021.08.044. View

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

Lee D, Kumar A, Mohammed T, Peres L, Alsina M, Bachmeier C . Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023; 7(16):4247-4257. PMC: 10424134. DOI: 10.1182/bloodadvances.2023009766. View

Ghosh A, Chen D, Guha A, Mackenzie S, Walker J, Roddie C . CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?. JACC CardioOncol. 2021; 2(1):97-109. PMC: 8352125. DOI: 10.1016/j.jaccao.2020.02.011. View

Khunger A, Battel L, Wadhawan A, More A, Kapoor A, Agrawal N . New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Curr Oncol Rep. 2020; 22(7):65. DOI: 10.1007/s11912-020-00925-8. View

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View

10.

Stein-Merlob A, Rothberg M, Holman P, Yang E . Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Curr Cardiol Rep. 2021; 23(3):11. PMC: 7821837. DOI: 10.1007/s11886-021-01440-3. View

11.

Marar R, Abbasi M, Prathivadhi-Bhayankaram S, Daryanani A, Villarraga H, Anavekar N . Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncol Pract. 2023; 19(6):331-342. DOI: 10.1200/OP.22.00713. View

12.

Lichtman A . The heart of the matter: protection of the myocardium from T cells. J Autoimmun. 2013; 45:90-6. PMC: 3783609. DOI: 10.1016/j.jaut.2013.05.004. View

13.

Shalabi H, Sachdev V, Kulshreshtha A, Cohen J, Yates B, Rosing D . Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer. 2020; 8(2). PMC: 7473612. DOI: 10.1136/jitc-2020-001159. View

14.

Lyon A, Lopez-Fernandez T, Couch L, Asteggiano R, Aznar M, Bergler-Klein J . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41):4229-4361. DOI: 10.1093/eurheartj/ehac244. View

15.

Patel N, Doukas P, Gordon L, Akhter N . Cardiovascular Toxicities of CAR T-cell Therapy. Curr Oncol Rep. 2021; 23(7):78. DOI: 10.1007/s11912-021-01068-0. View

16.

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

17.

Patel N, Dalal P, Meng Z, Baldridge A, Cascino G, Sunderraj A . Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy. Eur J Haematol. 2023; 112(1):102-110. DOI: 10.1111/ejh.14088. View

18.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

19.

Burns E, Gentille C, Trachtenberg B, Pingali S, Anand K . Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases. 2021; 9(1). PMC: 8006027. DOI: 10.3390/diseases9010020. View

20.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View